847829-41-8
847829-41-8 結(jié)構(gòu)式
基本信息
L-Alanine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-alanyl-L-α-aspartyl-
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-P2307 | Tat-NR2Baa Tat-NR2Baa | 847829-41-8 | 1mg | 2200元 |
| 2024/11/08 | HY-P2307 | Tat-NR2Baa Tat-NR2Baa | 847829-41-8 | 5mg | 5500元 |
| 2024/08/19 | HY-P2307 | Tat-NR2Baa Tat-NR2Baa | 847829-41-8 | 10mg | 9500元 |
常見問題列表
Tat-NR2BAA (125 ng; 20 mins) does not effects interactions between PSD-95 and NR2B subunits. In contrast, coimmunoprecipitation of PSD-95 with NR2B subunits is markedly decreased in rats pretreated with the disrupting peptide Tat-NR2B9c in lumbar dorsal horn tissue. Tat-NR2Baa (125 ng or 1.25 μg; 20 minutes before collection of lumbar dorsal horn tissue) is the control group of Tat-NR2B9c. Tat-NR2B9c produces a significant and robust reduction of postdischarge, indicating the hyperexcitability of the cell. But Tat-NR2Baa has no effects, even at a dose 100× greater than the active peptide Tat-NR2B9c (HY-P0117).Tat-NR2Baa (1 μM; pre-treatment 1 hour) is the control group in the Co-IP assay. Tat-NR2B9c (1 μM) disrupts NR2B/PSD95 interaction, and the coupling of NR2B to PSD-95 is more sensitive than NR2A/PSD95 to disruption in hippocampal neurons.